Breaking News
Ad-Free Version. Upgrade your experience. Save up to 40% More details

3 Biotech Stocks With Big News: RXII, CLVS, AZN

By Joshua RodriguezStock MarketsMay 10, 2016 09:48AM ET
3 Biotech Stocks With Big News: RXII, CLVS, AZN
By Joshua Rodriguez   |  May 10, 2016 09:48AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

RXI Pharmaceuticals Corp (NASDAQ:RXII)

On May 3, 2016 Rxi Pharmaceuticals announced that it had entered into a license agreement with Thera NeuroPharma for the treatment of ALS or Lou Gherig's Disease. ALS stands for amyotrophic lateral sclerosis, and is a debilitating disease where nerves in the muscles breakdown reducing/eliminating movement. Rxi entered the agreement with this private company to potentially improve the lives of these patients with no current treatment options.

Both Rxi and TheraNeuroPharma will use each others technology to find a new treatment option for these patients with ALS. Rxi will provide its mix RNA and RNAi hybrid technology sd-rxRNA together with Thera's small-molecule regenerative therapeutics platform. This deal is good for Rxi because TheraNeuroPharma will be responsible for all costs of the development, commercialization, manufacturing, and regulatory costs of the trial.

Both technologies will attempt to restore motor neurons in patients which become lost with the ALS disease. Current treatment for ALS is Rilutek, which slows down the progression of the disease but does not improve it. If both technologies achieve the goal of restoring motor neurons in the body, then they may significantly help restore muscles function in patients with ALS. There are around 20,000 people diagnosed with ALS, and currently is a huge unmet medical need.

Clovis Oncology Inc (NASDAQ:CLVS)

On May 5 Clovis Oncology announced that it would halt all clinical trials involving the use of its lung cancer drug rociletinib. In addition, the company announced that it would also reduce 35% of its workforce, because it is expecting the FDA to issue a notice that it will probably be rejecting the company's application for FDA approval. About a month ago the drug rociletinib was scrutinized at a panel healing where members were no impressed enough with the drug to vote for accelerated approval.

The FDA advisory panel voted 12 to 1 against approval for rociletinib in the treatment for EGFR lung cancer. Now one month later the company has been cutting back, and it expects to halt the trial, known as TIGER-3, which would have ran all the way to 2018 had it been completed. To make matters worse Clovis even announced that it would pull out on its European Application for rociletinib in the Eurozone.

Accelerated approval would have allowed Clovis to sell rociletnib earlier on the market than expected. It would have been able to do so without the completion of the phase 3 trial, TIGER-3. Unfortunately the data was mixed, and it could not prove that its drug was superior to Astrazeneca (NYSE:LON:AZN) Tagrisso. AstraZeneca had received FDA approval for Tagrisso to treat the same EFGR lung cancer patient population. This was a roadblock for Clovis, because to obtain accelerated approval a company must prove that its drug is superior to those that are already approved by the FDA.

All this is bad news for the rociletinib program, but the good news is that the company still boasts a pretty decent pipeline. The company is now focusing all efforts on an ovarian cancer drug rucaparib. Whether this drug will be successful or not remains to be seen, but the future of the company now hinges on this program. Once again Clovis is wanting to submit this drug on a rolling NDA submission which means that it will seek accelerated approval for this drug as well. As long as the data and safety support this NDA, the company may be able to recover.

Disclosure: Author is Long Rxi Pharmaceuticals (NASDAQ:RXII)

Original post

3 Biotech Stocks With Big News: RXII, CLVS, AZN

Related Articles

3 Biotech Stocks With Big News: RXII, CLVS, AZN

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email